This inventor holds 14 USPTO granted patents and 1 published patent application, plus 6 CIPO patents and 12 EPO patents. Top assignees: Pacific Edge Limited, Ludwig Institute for Cancer Research Limited, Pacific Edge Biotechnology Limited. Active years: 2008-2021.
Location History:
- East Taieri, NZ (2018)
- Dunedin, NZ (2008 - 2021)
Company Filing History:
13 out of 16 
1 out of 530 
1 out of 2 Years Active: 2008-2021
Title: Innovator Parry John Guilford: Pioneering Bladder Cancer Detection Methods
Introduction
Parry John Guilford, an esteemed inventor based in Dunedin, New Zealand, has made significant contributions to the medical field, particularly in the detection and treatment of bladder cancer. With a remarkable portfolio of 14 patents, Guilford's work is focused on enhancing diagnostic methods that can improve patient outcomes.
Latest Patents
Two of Guilford's latest patents showcase the advancements he has made in the realm of bladder cancer detection. The first patent outlines methods for the detection of specific markers associated with bladder cancer and inflammatory conditions of the bladder. This invention includes innovative techniques that improve the detection of genetic markers, ultimately aiding in the diagnosis and treatment of bladder-related health issues.
The second patent addresses the early detection of bladder tumors, a crucial factor in patient survival. This invention emphasizes the importance of urine markers, particularly members of the BTM or UBTM family, which can be found in both bladder tumor tissue and patient urine. Employing quantitative PCR methods, this invention reveals that detecting multiple BTMs or UBTMs can enhance the sensitivity and specificity in identifying bladder cancer. Furthermore, the introduction of kits simplifies the implementation of these methods, making them more accessible for clinical use.
Career Highlights
Throughout his career, Parry John Guilford has worked with innovative companies such as Pacific Edge Limited and Pacific Edge Biotechnology Limited. His experience in these organizations has allowed him to translate his research into practical applications that benefit both patients and healthcare providers.
Collaborations
Guilford has collaborated with notable colleagues, including Michael Alan Black and Jonathan Cebon. Their collective expertise has furthered the impact of his inventions, creating a synergy that enhances the development of effective diagnostic tools for bladder cancer.
Conclusion
Parry John Guilford stands out as a key figure in the ongoing quest for improved methods of bladder cancer detection and treatment. His 14 patents reflect a commitment to innovation, signaling hope for increased survival rates among patients. With continued research and collaboration, Guilford's contributions will likely pave the way for further advancements within the medical field.